HealthDay News – For patients taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and hospitalized with mild-to-moderate COVID-19, there is no significant difference in the mean number of days alive and out of the hospital with discontinuation or continuation of these medications, according to a study published in the January 19 issue of the Journal of the American Medical Association.
Renato D. Lopes, MD, PhD, from the D’Or Institute for Research and Education in Rio de Janeiro, and colleagues examined the impact of discontinuation versus continuation of ACEIs or ARBs on the number of days alive and out of hospital through 30 days among 659 patients hospitalized with mild-to-moderate COVID-19. Of the patients, 334 and 325 discontinued and continued ACEIs or ARBs, respectively.
The researchers observed no significant between-group difference in the number of days alive and out of the hospital (mean, 21.9 vs 22.9 for the discontinuation vs continuation groups; mean ratio, 0.95; 95% confidence interval, 0.90 to 1.01). The discontinuation and continuation groups showed no statistically significant difference in regards to death (2.7 vs 2.8%; odds ratio, 0.97; 95% confidence interval, 0.38 to 2.52), cardiovascular death (0.6 vs 0.3%; odds ratio, 1.95; 95% confidence interval, 0.19 to 42.12), or COVID-19 progression (38.3 vs 32.3%; odds ratio, 1.30; 95% confidence interval, 0.95 to 1.80).
“These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild-to-moderate COVID-19 if there is an indication for treatment,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.